Drugs / CD3+ Teff cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01163201 | Jan 2014 → Jan 2015 | Burkitt lymphoma, acute myeloid leukemia, blast phase chronic myelogenous leukemia, BCR-ABL1 positive, chronic lymphocytic leukemia/small lymphocytic lymphoma +8 | Masonic Cancer Center, University of Minnesota | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD3+ Teff cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01163201 ↗ |
| Modality | Cell therapy | “Biological: CD3+ Teff cells” NCT01163201 ↗ |
| Route | Other | “Given by infusion on Day 0 after transplantation” NCT01163201 ↗ |